RxDoctor Payments Data

Angela Reginelli, MD

Nephrology · New Orleans, LANPI 1972501229

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.6% of the total across 318 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 17.9% — the pattern of someone who eats at a lot of different presentations.

$6,341in general payments, 2019–2025

Across 318 payments — averaging $19.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • AstraZeneca$1K
  • Otsuka America Pharmaceutical, Inc.$596
  • Calliditas Therapeutics US Inc.$374
  • Akebia Therapeutics Inc$334
  • Mallinckrodt Hospital Products Inc.$291
  • plus $3K from 32 others

What the payments were for

  • Food & beverage$5,99795%
  • Education$3445%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,341 in reported general payments places this provider in the 80th percentile of 206 nephrology providers in Louisiana.

See all nephrology providers in Louisiana

Medicare billing

Part B allowed, 2024
$97,742
Medicare patients
184
Services billed
952

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JynarqueTolvaptan13$246,071
MounjaroTirzepatide124$150,127
JardianceEmpagliflozin79$112,448
FarxigaDapagliflozin Propanediol86$104,795
XphozahTenapanor Hcl11$31,778
Repatha SureclickEvolocumab43$27,873
ProliaDenosumab13$22,977
LinzessLinaclotide18$20,529
MyrbetriqMirabegron17$18,731
OzempicSemaglutide12$15,468
KerendiaFinerenone15$14,601
Sevelamer Carbonate39$8,787
RetacritEpoetin Alfa-Epbx14$2,822
Cinacalcet Hcl28$2,373
Nifedipine ErNifedipine97$2,233

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Jynarque$596$246,07113 claims
Lilly USA, LLCMounjaro$198$150,127124 claims
Boehringer IngelheimJardiance$125$112,44879 claims
AstraZenecaFarxiga$1,023$104,79586 claims
AmgenProlia$1,133$22,97713 claims
AbbVieLinzess, Synthroid$16$21,66230 claims
Novo NordiskOzempic$212$15,46812 claims
BayerKerendia$134$14,60115 claims
ANI Pharmaceuticals, Inc.Valsartan$27$49020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 206 nephrology providers in Louisiana.

Other nephrology in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →